Fundraising Fox

Sonavex

Baltimore, US · Founded 2013 · Delaware corporation · 25 employees on LinkedIn · 13 known investors

Sonavex develops medical device technologies focused on vascular access and related clinical applications, drawing on ultrasound-based imaging and monitoring products. The company serves clinical and surgical care settings, particularly in the dialysis and renal care space.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Sonavex was founded in 2013 by David Narrow, Devin O'Brien-Coon, and Jerry L. Prince.

DNDavid Narrow
David NarrowCo-founder
DO
Devin O'Brien-CoonCo-Founder & Chairman
JL
Jerry L. PrinceCo-Founder
JRJohn Rappe
John RappeExecutive
JPJerry Prince
Jerry PrinceNamed on SEC filing
AYAlex Yevzlin
Alex YevzlinNamed on SEC filing

Board

RH
Robert HallenbeckBoard director
MJ
Michael J. Hennessy, Jr.Board director
EPEvan Pritchard
Evan PritchardinBoard directorSenior Managing Director & Co-Founder at JStar Capital Investments
BNBill Niland
Bill NilandBoard director

Investors · 13

FusionPalo Alto · $500K – $1M
JStar Capital InvestmentsAustin
Keiretsu ForumSan Francisco · $250K – $2M
Maryland TEDCOUpper Marlboro · $500K – $1.5M
Rembrandt Venture PartnersLaramie
Riptide VenturesBaltimore · $750Kvia Mike Leffer · inferred
TEDCOColumbia
TMC Venture FundHouston
Unorthodox VenturesreportedAustin · $1M – $5M

Also in the syndicate · 4

GenHenn CapitalJSTAR CapitalOakwood Circle VenturesPartners Investment

Funding

SEC filings, press & company announcements

$37.5M disclosed across 7 of 8 rounds · 2015–2026

▶$3.1MraisedJul 2026 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonDirector
  • Alex YevzlinExecutive Officer
  • William NilandDirector
  • Robert HallenbeckDirector
  • Evan PritchardDirector
  • Michael J. Hennessy, Jr.Director
Offering amount
$15M
Amount sold
$3.1M
Proceeds to insiders
$400K
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedNov 2024 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill NilandDirector
  • John RappeExecutive Officer
  • David NarrowExecutive Officer, Director
  • Jerry PrinceDirector
  • Robert HallenbeckDirector
  • Devin O'Brien-CoonExecutive Officer, Director
  • Michael J. Hennessy, Jr.Director
Offering amount
$15M
Amount sold
$15M
Proceeds to insiders
$300K
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedNov 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Bill NilandDirector
  • Jerry PrinceDirector
  • Robert HallenbeckDirector
Amount sold
$1.8M
First sale
Oct 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedJan 2017 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill NilandDirector
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Jerry L. PrinceDirector
  • Robert HallenbeckDirector
Offering amount
$4.3M
Amount sold
$2.2M
Proceeds to insiders
$136K
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$320.2KraisedOct 2015 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Jerry PrinceDirector
Offering amount
$320.2K
Amount sold
$320.2K
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70KraisedJun 2015 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer
  • Devin O'Brien-CoonExecutive Officer, Director
Offering amount
$400K
Amount sold
$70K
Minimum investment
$5K
First sale
May 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Laminate Medical Technologies11 shared keywordsLaminate develops the VasQ extravascular support device, an implant that reinforces the anastomosis of arteriovenous fistulas to improve surgical outcomes for hemodialysis patients. The company operates in the medical device industry focused on vascular access for dialysis.
Sonovascular10 shared keywordsSonovascular is developing an interventional treatment for venous thromboembolism (VTE) that uses microbubble-mediated cavitation, delivered as a cath lab-based procedure without requiring ICU treatment. The company operates in the cardiovascular medical device space.
Neuwave Medical10 shared keywordsNeuWave Medical develops the NeuWave Microwave Ablation System, a device used by healthcare professionals to ablate soft tissue, including non-resectable liver tumors, in percutaneous, open surgical, and laparoscopic settings. The system includes a probe portfolio and ABLATE-IQ software for margin confirmation, and is marketed for use in the United States; the company is a wholly owned subsidiary of Quantum Surgical, Inc.

Companies competing with Sonavex for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Sonavex has filed a notice of an exempt offering of securities to raise $15 Million in New Funding. - intelligence360intelligence360.news · Aug 2026Baltimore kidney dialysis startup Sonavex raises $15 million - Baltimore Business Journalbizjournals.com · Oct 2024Sonavex Raises $15M to Support Novel Ultrasound Solutions - Sonavexsonavex.com · Oct 2024Sonavex Secures $15M Series A-2 Financing - Sonavexsonavex.com · Oct 2024Medical device startup Sonavex raises $3 million and is looking to hiretechnical.ly · Apr 2017The Johns Hopkins Center for Bioengineering Innovation & Design | CBID Startup, Sonavex, receives $3 million in funding - The Johns Hopkins Center for Bioengineering Innovation & Designcbid.bme.jhu.edu · Apr 2017

Frequently asked questions

What does Sonavex do?
Sonavex develops medical device technologies focused on vascular access and related clinical applications, drawing on ultrasound-based imaging and monitoring products. The company serves clinical and surgical care settings, particularly in the dialysis and renal care space.
Who founded Sonavex?
Sonavex was founded by David Narrow, Devin O'Brien-Coon, Jerry L. Prince in 2013.
Who are Sonavex's investors?
Sonavex's investors include Fusion, JStar Capital Investments, Keiretsu Forum, Maryland TEDCO, Rembrandt Venture Partners, Riptide Ventures, TEDCO, TMC Venture Fund and 1 more.
How much funding has Sonavex raised?
Sonavex has disclosed $37.5M raised across 7 of its 8 known rounds.
Where is Sonavex headquartered?
Sonavex is headquartered in Baltimore, US.